Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459494 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3459496 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL28509349 | 1.00 | PYGB (0.37) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL2397483 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL2848751 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7759963 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL6512434 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL7759960 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL2848748 | 0.93 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| Acetic Acid SCHEMBL30370283 | 0.83 | PYGB (0.42) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0961775-B1 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6509320-B1 | To treat an infection, an infestation, a neoplasm, or an autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-6479463-B1 | USED TO TREAT AN INFECTION, AN INFESTATION, A NEOPLASM, OR AN AUTOIMMUNE DISEASE OR TO MODULATE ASPECTS OF THE IMMUNE SYSTEM, INCLUDING MODULATION OF TH1 AND TH2 | ICN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | AVERETT DEVRON R (US) | 2002-05-16 | — | — | US | disclosed |
| CN-1296011-A | Purine L-nucleoside, its analogue and use thereof | ICN PHARMACEUTICALS (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1286258-A | Purine L-nucleoside, analogs and use thereof | ICN PHARMACEUTICALS (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-1072607-A2 | Purine L-nucleosides, analogs and uses therof | ICN Pharmaceuticals, Inc. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-0961775-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| CN-1233254-A | Purine L-nucleosides, analogs thereof and uses thereof | ICN PHARMACEUTICALS (US) | 1999-10-27 | — | — | CN | disclosed |
| WO-1998016184-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | PNP, NUDT1, TYMP | PYGB 1152/4885PYGL 245/4885PYGM 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.